Telomerase inhibition enhances apoptosis in human acute leukemia cells: Possibility of antitelomerase therapy

Leukemia

Volumn 17, Issue 3, 2003, Pages 560-567

  Nakajima, A ^a   Tauchi, T ^a   Sashida, G ^a   Sumi, M ^a   Abe, K ^b   Yamamoto, K ^b   Ohyashiki, J H ^a   Ohyashiki, K ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Acute leukemia; Apoptosis; DN hTERT

Indexed keywords

ANTILEUKEMIC AGENT; DAUNORUBICIN; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; TELOMERASE; TELOMERASE INHIBITOR; VINCRISTINE;

ACUTE LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOGENICITY; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; LYMPHATIC LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RESTRICTION FRAGMENT;

EID: 0037350830     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402825     Document Type: Article

References (47)

1. Blackburn E, Greider C (eds). Telomers. New York: Cold Spring Harbor Laboratory Press, 1995.
2. Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutat Res 1991; 256: 271-282.
3. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998; 92: 401-413.
4. de Lange T, Jacks T. For better or worse? Telomerase inhibition and cancer. Cell 1999; 98: 273-275.
5. Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci USA 1994; 91: 9857-9860.
6. Shay JW, Werbin H, Wright WE. Telomeres and telomerase in human leukemias. Leukemia 1996; 10: 1255-1261.
7. Engelhardt M, Kumar R, Albanell J, Pettengell R, Han R, Moore MAS. Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood 1997; 90: 182-193.
8. Ohyashiki JH, Ohyashiki K, Iwama H, Hayashi S, Toyama K, Shay JW. Clinical implications of telomerase activity levels in acute leukemia. Clin Cancer Res 1997; 3: 619-625.
9. Engelhardt M, Mackenzie K, Drullinsky P, Silver RT, Moore MA. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res 2000; 60: 610-617.
10. Brummendorf TH, Holyoake TL, Rufer N, Barnett MJ, Schulzer M, Eaves CJ et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood 2000; 95: 1883-1890.
11. Hu BT, Insel RA. Up-regulation of telomerase in human B lymphocytes occurs independently of cellular proliferation and with expression of the telomerase catalytic subunit. Eur J Immunol 1999; 29: 3745-3753.
12. Chaves-Dias C, Hundley TR, Gilfillan AM, Kirshenbaum AS, Cunha-Melo JR, Metcalfe DD et al. Induction of telomerase activity during development of human mast cells from peripheral blood CD34+ cells: comparisons with tumor mast-cell lines. J Immunol 2001; 166: 6647-6656.
13. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279: 349-352.
14. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ. Both Rb/pl6INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998; 396: 84-88.
15. Jiang XR, Jimenetz G, Chang E. Frolkis M, Kusler B, Sage M et al. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nature Genet 1999; 21: 111-114.
16. Morales CP, Holt SE, Ouellette M, Kaur KJ, Van Y, Wilson KS et al. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet 1999; 21: 115-118.
17. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumor cells with defined genetic elements. Nature 1999; 400: 464-468.
18. Wang J, Hannon GJ, Beach DH. Risky immortalization by telomerase. Nature 2000; 405: 755-756.
19. Weitzman JB, Yaniv M. Rebuilding the road to cancer. Nature 1999; 400: 401-402.
20. Hahn CW, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999; 5: 1164-1170.
21. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 1999; 13: 2388-2399.
22. Ohyashiki K, Fujieda H, Miyauchi J, Ohyashiki JH, Tauchi T, Saito M et al. Establishment of a novel heterotransplantable acute lymphoblastic leukemia cell line with a t(17;19) chromosomal translocation the growth of which is inhibited by interleukin-3. Leukemia 1991; 5: 322-331.
23. Tauchi T, Yoshimura A, Ohyashiki K. CIS1, a cytokine-inducible SH2 protein, suppresses BCR-ABL-mediated transformation: involvement of the ubiquitin proteasome pathway. Exp Hematol 2001; 29: 356-361.
24. Ohyashiki JH, Ohyashiki K, Toyama K, Shay JW. A nonradioactive. fluorescence-based telomeric repeat amplification protocol to detect and quantitate telomerase activity. Trends Genet 1996; 12: 395-396.
25. Yahata N, Ohyashiki K, Ohyashiki JH, Iwama H, Hayashi S, Ando K et al. Telomerase activity in lung cancer cells obtained from bronchial washings. J Natl Cancer Inst 1998; 90: 684-690.
26. Iwama H, Ohyashiki K, Ohyashiki JH, Hayashi S, Yahata N, Ando K et al. Telomeric length and telomerase activity vary with age in peripheral blood cells obtained from normal individuals. Hum Genet 1998; 102: 397-402.
27. Nakajima A, Tauchi T, Ohyashiki K. ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis. Leukemia 2001; 15: 989-990.
28. Rufer N, Brummendorf TH, Kolvraa S, Bischoff C, Christensen K, Wadsworth L et al. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med 1999; 190: 157-167.
29. Shin-ya K, Wierzba K, Matsuo K, Ohtani T, Yamada Y, Furihata K et al. Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus. J Am ChemSoc 2001; 123: 1262-1263.
30. Kim MY, Vankayalapati H, Shin-ya K, Wierzba K, Hurley LH. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex. J Am Chem Soc 2002; 124: 2098-2099.
31. Kilian A, Bowtell DD, Abud HE, Hime GR, Venter DJ, Keese PK et al. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet 1997; 6: 2011-2019.
32. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 1998; 58: 4168-172.
33. Wick M, Zubov D, Hagen G. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 1999; 232: 97-106.
34. Colgin LM, Wilkinson C, Englezou A, Kilian A, Robinson MO, Reddel RR. The hTERT alpha splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia 2000; 2: 426-432.
35. Aisner DL, Wright WE, Shay JW. Telomerase regulation: not just flipping the switch. Curr Opin Genet Dev 2002; 12: 80-85.
36. Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V, Cech TR. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 1997; 276: 561-567.
37. Sachsinger J, Gonzalez-Suarez E, Samper E, Heicappell R, Muller M, Blasco MA. Telomerase inhibition in RenCa, a murine tumor cell line with short telomeres, by overexpression of a dominant negative mTERT mutant, reveals fundamental differences in telomerase regulation between human and murine cells. Cancer Res 2001; 61: 5580-5586.
38. Liu JP. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J 1999; 13: 2091-2104.
39. Buchkovich KJ, Greider CW. Telomerase regulation during entry into the cell cycle in normal human T cells. Mol Biol Cell 1996; 7: 1443-1454.
40. Kondo S, Kondo Y, Li G, Silverman RH, Cowell JK. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 1998; 16: 3323-3330.
41. Glukhov AI, Zimnik OV, Gordeev SA, Severin SE. Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonucleotides. Biochem Biophys Res Commun 1998; 248: 368-371.
42. Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 2001; 20: 6958-6968.
43. Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogens 2002; 21: 680-687.
44. Lee KH, Rudolph KL, Ju YJ, Greenberg RA, Cannizzaro L et al. Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc Natl Acad Sci USA 2001; 98: 3381-3386.
45. Baur JA, Zou Y, Shay JW, Wright WE. Telomere position effect in human cells. Science 2001; 292: 2075-2077.
46. Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000; 406: 641-645.
47. Wright WE, Shay JW. Telomere dynamics in cancer progression and prevention: fundamental differences in human and mouse telomere biology. Nat Med 2000; 6: 849-851.